Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes
- PMID: 30275257
- PMCID: PMC6314916
- DOI: 10.3899/jrheum.180158
Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes
Abstract
Objective: Pregnancies in women with active rheumatic disease often result in poor neonatal outcomes. Hydroxychloroquine (HCQ) reduces disease activity and flares; however, pregnancy causes significant physiologic changes that may alter HCQ levels and lead to therapeutic failure. Therefore, our objective was to evaluate HCQ concentrations during pregnancy and relate levels to outcomes.
Methods: We performed an observational study of pregnant patients with rheumatic disease who were taking HCQ from a single center during 2013-2016. Serum samples were analyzed using high-performance liquid chromatography/mass spectrometry. Primary HCQ exposure was categorized as nontherapeutic (≤ 100 ng/ml) or therapeutic (> 100 ng/ml). Categorical outcomes were analyzed using Fisher's exact test and continuous outcomes using linear regression models, Wilcoxon signed-rank test, Kruskal-Wallis test, t test, and ANOVA.
Results: We analyzed 145 samples from 50 patients with rheumatic disease, 56% of whom had systemic lupus erythematosus (SLE). HCQ concentration varied widely among individuals at each trimester. Mean physician's global assessment scores in patients with SLE were significantly higher in those with average drug levels ≤ 100 ng/ml compared to > 100 ng/ml (0.93 vs 0.32, p = 0.01). Of patients with SLE, 83% with average drug levels ≤ 100 ng/ml delivered prematurely (n = 6), compared to only 21% with average levels > 100 ng/ml (n = 19; p = 0.01). HCQ levels were not associated with prematurity or disease activity in non-SLE patients.
Conclusion: With both high and low HCQ levels associated with preterm birth and disease activity in SLE, further study is necessary to understand HCQ disposition throughout pregnancy and to clarify the relationship between drug levels and outcomes.
Keywords: HYDROXYCHLOROQUINE; PREGNANCY; SYSTEMIC LUPUS ERYTHEMATOSUS.
Figures
Comment in
-
Too Little of a Good Thing: Hydroxychloroquine in Pregnancy.J Rheumatol. 2019 Jan;46(1):1-2. doi: 10.3899/jrheum.181046. J Rheumatol. 2019. PMID: 30600233 No abstract available.
Similar articles
-
Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in systemic lupus erythematosus patients.Rheumatology (Oxford). 2025 Mar 1;64(3):1225-1233. doi: 10.1093/rheumatology/keae302. Rheumatology (Oxford). 2025. PMID: 38837707 Free PMC article.
-
Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.Arthritis Care Res (Hoboken). 2016 Sep;68(9):1295-302. doi: 10.1002/acr.22837. Epub 2016 Jul 27. Arthritis Care Res (Hoboken). 2016. PMID: 26749299
-
Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.Lupus. 2019 Jun;28(7):862-867. doi: 10.1177/0961203319851558. Epub 2019 May 24. Lupus. 2019. PMID: 31122136
-
Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis.Joint Bone Spine. 2018 Dec;85(6):663-668. doi: 10.1016/j.jbspin.2018.03.006. Epub 2018 Apr 6. Joint Bone Spine. 2018. PMID: 29631068
-
Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis.Lupus. 2021 Jun;30(7):1163-1174. doi: 10.1177/09612033211007199. Epub 2021 Apr 15. Lupus. 2021. PMID: 33853420
Cited by
-
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.Ther Adv Musculoskelet Dis. 2022 Feb 14;14:1759720X211073001. doi: 10.1177/1759720X211073001. eCollection 2022. Ther Adv Musculoskelet Dis. 2022. PMID: 35186126 Free PMC article. Review.
-
The relationship between hydroxychloroquine plasma concentration and COVID-19 outcomes in rheumatoid arthritis patients in Saudi Arabia.Saudi Pharm J. 2022 Jul;30(7):964-970. doi: 10.1016/j.jsps.2022.05.006. Epub 2022 May 23. Saudi Pharm J. 2022. PMID: 35645589 Free PMC article.
-
Whole blood hydroxychloroquine: Does genetic polymorphism of cytochrome P450 enzymes have a role?Clin Exp Med. 2023 Dec;23(8):4141-4152. doi: 10.1007/s10238-023-01142-w. Epub 2023 Jul 22. Clin Exp Med. 2023. PMID: 37480404 Review.
-
Perspectives of Adult Rheumatologists Regarding Family Planning Counseling and Care: A Qualitative Study.Arthritis Care Res (Hoboken). 2020 Mar;72(3):452-458. doi: 10.1002/acr.23872. Arthritis Care Res (Hoboken). 2020. PMID: 30875455 Free PMC article.
-
Maternal exposure to hydroxychloroquine and birth defects.Birth Defects Res. 2021 Oct 15;113(17):1245-1256. doi: 10.1002/bdr2.1943. Epub 2021 Jul 23. Birth Defects Res. 2021. PMID: 34296811 Free PMC article.
References
-
- Peart E, Clowse ME. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. Curr Opin Rheumatol 2014;26:118–23. - PubMed
-
- Ostensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse ME, et al. State of the art: Reproduction and pregnancy in rheumatic diseases. Autoimmun Rev 2015;14:376–86. - PubMed
-
- Clowse ME. Managing contraception and pregnancy in the rheumatologic diseases. Best Pract Res Clin Rheumatol 2010;24:373–85. - PubMed
-
- de Man YA, Hazes JM, van der Heide H, Willemsen SP, de Groot CJ, Steegers EA, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum 2009;60:3196–206. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical